2023
Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke
Sperber P, Gebert P, Broersen L, Kufner A, Huo S, Piper S, Teegen B, Heuschmann P, Prüss H, Endres M, Liman T, Siegerink B. Depressive symptoms and anti-N-methyl-D-aspartate-receptor GluN1 antibody seropositivity in the PROSpective cohort with incident stroke. Brain Behavior & Immunity - Health 2023, 34: 100705. PMID: 38033615, PMCID: PMC10684375, DOI: 10.1016/j.bbih.2023.100705.Peer-Reviewed Original ResearchNMDAR1-ABDepressive symptomsHigh titersIschemic strokeProspective cohortEpidemiological Studies Depression ScaleSevere neuropsychiatric symptomsSevere depressive symptomsAutoimmune encephalitisSeronegative patientsAntibody seropositivityIncident strokeSeropositive patientsNeuropsychiatric symptomsSymptoms yearsPatientsLow titersSymptomsTitersCell-based assaysSeropositivityCohortStrokeCESEncephalitisMachine learning-based prediction of clinical outcomes after first-ever ischemic stroke
Fast L, Temuulen U, Villringer K, Kufner A, Ali H, Siebert E, Huo S, Piper S, Sperber P, Liman T, Endres M, Ritter K. Machine learning-based prediction of clinical outcomes after first-ever ischemic stroke. Frontiers In Neurology 2023, 14: 1114360. PMID: 36895902, PMCID: PMC9990416, DOI: 10.3389/fneur.2023.1114360.Peer-Reviewed Original ResearchMini-Mental State ExaminationClinical outcomesBarthel IndexIschemic strokePrognostic factorsPatient dischargeCognitive functionFunctional recovery outcomesFurther patient careHealth Stroke ScaleEpidemiologic Studies Depression ScaleIschemic stroke patientsStroke ScaleAcute strokeProspective cohortRankin ScaleFunctional recoveryPrognostic featuresStroke patientsModified Telephone InterviewTreatment strategiesDepression ScaleIndividual patientsState ExaminationHealthcare providers
2022
Low ankle-brachial index and cognitive function after stroke—the PROSpective with Incident Stroke Berlin (PROSCIS-B)
Stillfried M, Sperber P, Broersen L, Huo S, Piper S, Heuschmann P, Endres M, Siegerink B, Liman T. Low ankle-brachial index and cognitive function after stroke—the PROSpective with Incident Stroke Berlin (PROSCIS-B). Frontiers In Neurology 2022, 13: 963262. PMID: 36247749, PMCID: PMC9554657, DOI: 10.3389/fneur.2022.963262.Peer-Reviewed Original ResearchLow ankle-brachial indexAnkle-brachial indexCognitive functionIschemic strokeRelative riskCognitive impairmentMontreal Cognitive AssessmentGeneralized atherosclerosisProspective cohortRisk factorsGeneral populationState ExaminationCognitive declinePatientsCognitive statusTelephone interviewsMini-MentalCognitive AssessmentStrokeBaselineImpairmentRiskMixed modelsTICSAtherosclerosisSerum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)
Sperber P, Gebert P, Broersen L, Huo S, Piper S, Teegen B, Heuschmann P, Prüss H, Endres M, Liman T, Siegerink B. Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B). Journal Of Neurology 2022, 269: 5521-5530. PMID: 35718820, PMCID: PMC9468072, DOI: 10.1007/s00415-022-11203-x.Peer-Reviewed Original ResearchConceptsSeronegative patientsIschemic strokeCognitive functionNMDAR1-ABLow titersHigh titersFavorable cognitive outcomeModerate ischemic strokeAntibody seropositivityProspective cohortReceptor antibodiesSerum titersPatientsSeropositivityCognitive statusStrokeTelephone interviewsInverse probabilityTitersCognitive outcomesCell-based assaysTICSLong termSerostatusResultsData
2020
Endothelial and Leukocyte-Derived Microvesicles and Cardiovascular Risk After Stroke: PROSCIS-B.
Huo S, Kränkel N, Nave A, Sperber P, Rohmann J, Piper S, Heuschmann P, Landmesser U, Endres M, Siegerink B, Liman T. Endothelial and Leukocyte-Derived Microvesicles and Cardiovascular Risk After Stroke: PROSCIS-B. Neurology 2020, 96: e937-e946. PMID: 33184230, DOI: 10.1212/wnl.0000000000011223.Peer-Reviewed Original ResearchConceptsPlatelet-derived MVsCardiovascular outcomesCause mortalityMyocardial infarctionLong-term cardiovascular outcomesCox proportional hazards modelLeukocyte-derived microvesiclesClass II evidenceWorse cardiovascular outcomesLong-term prognosisKaplan-Meier curvesPlatelet-derived microvesiclesProportional hazards modelRecurrent strokeCardiovascular riskEndothelial dysfunctionIschemic strokeProspective cohortHighest quartileStroke patientsVascular inflammationMild strokeEndothelial microvesiclesLowest quartileHazards modelCoagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke
Rohmann J, Huo S, Sperber P, Piper S, Rosendaal F, Heuschmann P, Endres M, Liman T, Siegerink B. Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke. Journal Of Thrombosis And Haemostasis 2020, 18: 3316-3324. PMID: 32935900, DOI: 10.1111/jth.15092.Peer-Reviewed Original ResearchConceptsFirst ischemic strokeIschemic strokeCoagulation factor XIIVascular outcomesHazard ratioRisk factorsActivity levelsFactor XIICox proportional hazards modelIschemic stroke eventsRecurrent vascular eventsWorse vascular outcomesCardiovascular risk factorsIschemic stroke patientsFirst thrombotic eventSecondary eventsProportional hazards modelModerate ischemic stroke patientsFactor activity levelsRecurrent strokeCause mortalityProspective cohortVascular eventsThrombotic eventsStroke events
2019
Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)
Sperber P, Siegerink B, Huo S, Rohmann J, Piper S, Prüss H, Heuschmann P, Endres M, Liman T. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke 2019, 50: 3213-3219. PMID: 31526121, DOI: 10.1161/strokeaha.119.026100.Peer-Reviewed Original ResearchConceptsSecondary vascular eventsFunctional outcomeVascular eventsHigh titersNMDAR1-ABSeronegative patientsSeropositive patientsFirst strokeLong-term clinical outcomesLong-term functional outcomeCombined end pointRecurrent vascular eventsOutcomes of patientsPoor functional outcomeSub-group analysisOutcomes of interestAnti-NMDAAutoimmune encephalitisCardiovascular riskProspective cohortRankin ScaleHazard ratioClinical outcomesNeuroprotective effectsReceptor antibodies